Patent · US Expired

Affinity enhancement immunological reagents for in vivo detection and killing of specific target cells

US5256395A · kind A · utility

90Cited by
20References
25Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 10, 1987
Grant dateOct 26, 1993
Priority date
Expiry dateSep 10, 2007

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2123/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Immunological reagents, consisting of a) antibody or fragment conjugates having both an anti-cell specificity and an anti-hapten specificity, and b) synthetic tracers containing at least two hapten sites and at least one site suitable to attach radioactive isotopes, paramagnetic ions, drugs or toxins, are provided. These reagents are capable of binding to target cells in a specific way, and the tracer localizes preferentially on the membrane of antigen-bearing cells, even in the presence of excess antibody conjugate (affinity enhancement). These reagents are usefully employed, either in vitro or in vivo, to detect tumors, metastases, or other tissue injuries, when the synthetic tracer carries radioactive or paramagnetic compounds, and to kill target cells when the synthetic tracer carries radioactive compounds or drugs or toxins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.